Cwm LLC boosted its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Get Rating) by 63.0% in the third quarter, Holdings Channel.com reports. The fund owned 176 shares of the company’s stock after acquiring an additional 68 shares during the quarter. Cwm LLC’s holdings in Medpace were worth $28,000 at the end of the most recent quarter.
A number of other large investors also recently bought and sold shares of MEDP. Ronald Blue Trust Inc. lifted its holdings in shares of Medpace by 59.8% in the 3rd quarter. Ronald Blue Trust Inc. now owns 187 shares of the company’s stock worth $28,000 after buying an additional 70 shares during the period. Wipfli Financial Advisors LLC purchased a new stake in shares of Medpace during the 3rd quarter worth $32,000. Point72 Hong Kong Ltd purchased a new stake in shares of Medpace during the 2nd quarter worth $42,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Medpace during the 3rd quarter worth $46,000. Finally, Parkside Financial Bank & Trust purchased a new stake in shares of Medpace during the 2nd quarter worth $50,000. Hedge funds and other institutional investors own 82.49% of the company’s stock.
In other news, General Counsel Stephen P. Ewald sold 6,500 shares of the stock in a transaction dated Thursday, October 27th. The stock was sold at an average price of $220.53, for a total value of $1,433,445.00. Following the transaction, the general counsel now directly owns 14,854 shares of the company’s stock, valued at $3,275,752.62. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 20.60% of the company’s stock.
Medpace Price Performance
Medpace (NASDAQ:MEDP – Get Rating) last announced its earnings results on Monday, October 24th. The company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.58. The company had revenue of $383.74 million for the quarter, compared to analyst estimates of $357.17 million. Medpace had a return on equity of 41.39% and a net margin of 16.50%. The firm’s quarterly revenue was up 29.8% compared to the same quarter last year. During the same period in the prior year, the company posted $1.29 EPS. On average, analysts expect that Medpace Holdings, Inc. will post 6.97 EPS for the current year.
Analysts Set New Price Targets
MEDP has been the subject of a number of analyst reports. StockNews.com cut Medpace from a “buy” rating to a “hold” rating in a research note on Friday, October 28th. UBS Group upgraded Medpace from a “sell” rating to a “neutral” rating and upped their price objective for the stock from $142.00 to $238.00 in a research note on Thursday, October 27th. Finally, Robert W. Baird upped their target price on Medpace from $217.00 to $226.00 in a research report on Friday, January 13th.
Medpace Company Profile
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
- Get a free copy of the StockNews.com research report on Medpace (MEDP)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.